If approved by the FDA to treat post-traumatic stress disorder, MDMA – the party drug known as “Molly” or “ecstasy” – will be prepared for shipping to the market by Sharp from Phoenixville, writes Will Yakowicz for Inc. magazine.

The pharmaceutical packaging company would put the drug into capsules after being manufactured by British Onyx.

Rick Doblin, the founder and director of Multidisciplinary Association for Psychedelic Studies, a nonprofit, has been working on getting the drug approved as medicine for 32 years.

Doblin spent the early 1980s studying various psychedelics. He once witnessed a survivor of sexual assault overcome her suicidal thoughts by combining MDMA with psychotherapy sessions.

[uam_ad id=”71803″]

Advertisement

“I saw the power of MDMA,” said Doblin. “It was a turning point, and I knew what I wanted to do with my life.”

After the drug was banned by the government in 1985, Doblin began his journey to reclaim it as medicine.

Decades later, he’s one step closer to convincing the FDA that, when combined with psychotherapy, MDMA is a safe and effective treatment for PTSD. Doblin is ready to start Phase III clinical trials this summer. With good results, he hopes to get FDA approval by 2021.

Read more about the potential treatment for post-traumatic stress disorder in Inc. magazine here.

[uam_ad id=”73615″]